Seeking Alpha

Marty Chilberg's  Instablog

Marty Chilberg
Send Message
I'm a retired CPA who spent the majority of his working career in technology companies. My work included management stints at Atari Inc, Daisy Systems Corp, Symantec Corp and Visio Corp. My last position at Visio (VSIO) was as CFO and VP Finance and Operations.
View Marty Chilberg's Instablogs on:
  • Quest Diagnostics NIPT Comments $DGX

    Stephen Rusckowski - President and CEO opening remarks

    - These are all exciting opportunities for us. This last win is further evidence that hospital leaders are open to new ideas to help them manage the emerging challenges of reimbursement pressure and lower utilization. We have the experience and expertise to help tailor solutions for the needs to hospitals of all shapes and sizes.

    Finally, we are seeing results from our focus on specific disease stay-in conditions. We talked about the strong growth in our Wellness business, combining with Summit Health, will strengthen this business. We have also seen solid growth in our toxicology and prescription drug monitoring offerings, as well as improvements in Hepatitis C, BRC Advantage, and non-invasive prenatal testing.

    Question-and-Answer Session

    Stephen Rusckowski - President and CEO

    But also non-evasive prenatal testing is a growth market for us, we're focused on that as well. We feel that with the progress we're making there we think it's a fast growth market place. It is a great example where medical guidelines are actually stimulating demand for us and we're taking advantage of those new guidelines of the market place.

    Mark Guinan - CFO

    Yeah. We have successfully negotiated reimbursement rates with the typical health plans that we contract with. We feel good about the prices again similar to what Steve said on expectation as not just volume but the reimbursement rates that we thought we could achieve. We're feeling good about those. So, the reimbursement environment is reasonable certainly like any other task that starts to get lot more attention - the payers start to put some things in place like pre-authorizations, etc. that can slow down the process, make things a little cumbersome and you're going to work through some of those issues initially to smooth up the process but no major hurdles on reimbursement in those two categories right now.

    Apr 24 8:27 PM | Link | Comment!
  • In Country Sequencing Is The Future

    This podcast with Cliff Reid of Complete Genomics is very interesting. Includes discussion of why China FDA decided to step in to regulate NG sequencing (no CLIA regs). Also note the 15 minute mark where it's clear that sequencing will be done in-country in future. Clearly seems to indicate labs such as Life Codexx and Lab Cerba are going to be critical for NIPS. Lots of sequencing equipment to be sold in future. Illumina is current leader.

    mendelspod.com/podcast/cliff-reid-regulation-and-genomic-medicine

    Disclosure: I am long SQNM.

    Apr 22 11:03 AM | Link | Comment!
  • Carrier Screening Info

    Note Sequenom carrier screen HerediT Cystic Fibrosis did about 33,000 tests in 2013, up about 20% from 2012.

    US Cystic Fibrosis Carrier Screening Market Swells to More than US$ 300 Million

    According to a new research report by RNCOS entitled, "Genetic Testing Market Outlook to 2017", more and more would be American parents are opting for cystic fibrosis (CF) carrier screening test to assess the chances of having a baby suffering with cystic fibrosis. The private sector is actively participating in this robust field attracted by the more than 1 Million CF carrier screening tests that are performed each year in the US. With an average reimbursement rate of US$ 200- 400 per test; the US market is estimated to be in excess of US$ 300 Million per year and witness a high digit growth rate in future.

    Coverage of Carrier Screening

    Tuesday, September 24, 2013

    This message is regarding genetic tests used to determine carrier status for cystic fibrosis (CF), Fragile X, and spinal muscular atrophy (SMA). Consistent with the recommendations set forth by ACMG and ACOG, OHCA considers CF carrier screening using the common mutation panel (CPT code 81220) to be medically necessary once in a lifetime for women of reproductive age and the partners of those that test positive. Expanded mutation panels beyond those recommended by ACMG/ACOG are not considered medically necessary and will be reimbursed at a rate that is based on the common variant panel alone. OHCA does not consider other carrier screening in the general population to be medically necessary. In particular, carrier screening for Fragile X (CPT code 81243) and SMA (CPT code 81401) are not considered medically necessary in the absence of a family history suggestive of those conditions. This is consistent with the ACOG and ACMG recommendations for Fragile X carrier screening and the ACOG recommendations for SMA carrier screening.

    Disclosure: I am long SQNM.

    Apr 18 7:39 PM | Link | Comment!
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.